Born 1972. Deputy Chief Executive Officer and responsible for the duties of the Chief Financial Officer and Chief Commercial Officer. Joined in 2020.
Professional background: Julie Waras Brogren has more than 20 years experience from life science leadership and commercialization, including cross-functional drug launches and medical devices. Julie was previously President of BresoTEC, Canada and has held various leadership positions at Novo Nordisk in Denmark and Latin America, including as Senior Director of the Launch Office for the Victoza® GLP-a and degludec insulin launches. Julie also has board experience from life science companies. She started her career at Accenture. Julie joined Ascelia in 2020 as CCO and in 2022 she also became Deputy CEO. Since 2023, she is also responsible for the duties of CFO and Investor Relations.
Education: M.Sc. in International Business from Copenhagen Business School and Diplome ESC, EM Lyon France, including studies at Chinese University of Hong Kong.
Other ongoing assignments: Board member of Pila Pharma AB, Implexion Pharma and Board member of Ascelia Pharma Inc.
Holdings in Ascelia: View holdings